When consumers choose lactase, what they really care about is often not how “high the enzyme activity is,” but rather two more fundamental questions: Is it safe? And will it actually work? Particularly for infants and young children, individuals with lactose intolerance, and those seeking functional nutritional supplementation, lactase is not merely an enzyme preparation—it is a solution directly linked to digestive comfort, nutrient‑absorption efficiency, and long‑term safety. It is against this backdrop of such needs that NEWGENBIO® Acidic Lactase has been steadily developed. Rather than simply pursuing “higher activity,” it has built a more comprehensive lactase technology platform, centered on the human body’s real‑world digestive environment, international testing standards, end‑to‑end quality control, and versatile dosage‑form applications.

With nearly 20 years of technological expertise, we have helped propel lactase toward international standards.

 

Why NEWGENBIO® Is acidic lactase more competitive?

 

Truly superior lactase isn’t judged solely by its activity label; it also depends on whether it has established a comprehensive system for safety and efficacy. In this regard, NEWGENBIO® has developed a relatively complete technological closed-loop.

Patented lactase technology, with higher activity.

NEWGENBIO®’s patented acidic lactase boasts comprehensive advantages—high activity, multiple specifications, and broad compatibility—and can be widely applied across various dosage forms and manufacturing processes.

 

· Active ingredient in liquid products Up to 70,000 ALU/mL , and can be directly used in drop formulations or dairy systems;

· Powdered products are available 100,000 ALU/g, 160,000 ALU/g Available in a variety of standard specifications, suitable for solid dosage forms such as formulated milk powder, tablets, and capsules.

· In addition, Synoa exclusively offers an ultra-high‑activity grade of 200,000 ALU/g, suitable for a variety of applications, including ultra‑thin tablet compression.

 

 

 

More stable process control capability

The rigorous construction of a digital factory emphasizes quality consistency and batch-to-batch stability across the entire process—from strain development and fermentation to extraction, filtration, and packaging—thereby minimizing uncertainties arising from exogenous impurities and process variability.

 

 

A more comprehensive security system

NEWGENBIO® acidic lactase has undergone comprehensive safety assessments, including acute oral toxicity and genotoxicity studies, and is steadily advancing the establishment of an international compliance system. To date, it has been submitted for regulatory approval. FDA GRAS , Successfully registering the Drug Master File in the United States ensures that lactase is not only “usable” but also “safe to use.”

 

Broader application compatibility

Whether it’s for infants and young children, adults with lactose intolerance, or in the fields of pet nutrition, functional foods, and dietary supplements, NEWGENBIO® All are striving to meet increasingly diverse application needs by leveraging different dosage forms and active‑ingredient ranges.

 

 

From early research on lactase preparations, through localized industrialization, to an acidic lactase system that better aligns with the human body’s physiological environment, NEWGENBIO® aims to deliver not just a single lactase product, but a comprehensive solution for lactose intolerance—safer, more stable, and better suited to modern nutritional needs.

—About NEWGEN—About Us

 

Ningbo Xinoya Marine Biotechnology Co., Ltd. is located in Xiangshan County, Ningbo City. Founded in 2013, it is a high-tech enterprise established by Zhu Hui, an immunology expert who returned to China after studying in the United States. Grounded in marine biological resources, the company leverages synthetic biology technologies to develop natural bioactive macromolecular products derived from marine organisms, with the aim of delivering intestinal nutrition and health solutions and advancing nutritional health services.

 

 

The company ranks among the world’s leaders in marine polysaccharides, marine enzyme preparations, and intestinal microbiome research. Leveraging its robust capabilities and cutting-edge technologies in the marine biopharmaceutical sector, it has undertaken numerous national, provincial, and municipal R&D projects, including the National “13th Five-Year Plan” Marine Innovation Development and Demonstration Project, Ningbo City’s “2025 Science and Technology Breakthrough” Major Special Project, and Ningbo City’s “Challenge‑Based Recruitment” Major Special Project, among others.

 

 

The company has obtained multiple quality‑management certifications, including ISO 22000:2015 for food safety management, ISO 9001:2015 for quality management, HACCP for food safety, as well as Kosher, Halal, and NSF‑CGMP. It is a member of several international associations, such as the International Probiotics Association (IPA) and the Enzyme Technical Association (ETA), and has been awarded numerous provincial and municipal honors for technological innovation, including the Third Prize of the China Council for the Promotion of International Trade Science and Technology Award, the Second Prize of the China Invention Association, and the Third Prize of the Ningbo Science and Technology Progress Award. The company places great emphasis on intellectual property protection; by 2023, it had filed more than 70 patent applications and been granted 36 patents, including 23 invention patents.